Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Kanagawa, Japan; Department of Respiratory Medicine, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Clinical Research Center for Allergy and Rheumatology, Sagamihara National Hospital, Sagamihara, Kanagawa, Japan.
J Allergy Clin Immunol Pract. 2018 Jan-Feb;6(1):116-125.e3. doi: 10.1016/j.jaip.2017.04.035. Epub 2017 Jun 2.
The pathogenesis of aspirin-exacerbated respiratory disease (AERD) is characterized by the low expression of cyclooxygenase-2 (COX-2) in airway epithelia, which decreases the production of prostaglandin E (PGE). Conversely, cigarette smoke stimulates COX-2 expression in airway epithelia. Therefore, it was hypothesized that the development of AERD would be suppressed by elevated PGE levels in smokers, and smoking cessation might increase susceptibility to AERD.
The objective of this study was to evaluate the relationship between smoking and the risk of AERD development.
The smoking status of patients with AERD (n = 114) was compared with 2 control groups with aspirin-tolerant asthma (ATA), patients diagnosed by a systemic aspirin provocation test (ATA-1, n = 83) and outpatients randomly selected from a large-scale dataset (ATA-2, n = 914), as well as a healthy control group (HC, n = 2313).
At the age of asthma onset, there was a low frequency of current smokers (9.7%), but a high frequency of past smokers (20.2%) in the AERD group compared with the ATA-1 (20.5% and 12.0% for current and past smokers, respectively), ATA-2 (24.5% and 10.3%, respectively), and HC group (26.2% and 12.6%, respectively). After adjustment for confounding variables, AERD was positively associated with smoking cessation between 1 and 4 years before disease onset compared with the ATA-2 group (adjusted odds ratio [aOR] 4.63, 95% confidence interval [CI]: 2.16-9.93) and the HC group (aOR 4.09, 95% CI: 2.07-8.05), implying that smoking cessation was followed by the development of AERD.
Smoking cessation may be a risk factor for the development of AERD.
阿司匹林加重型呼吸系统疾病(AERD)的发病机制表现为气道上皮中环氧化酶-2(COX-2)表达降低,导致前列腺素 E(PGE)生成减少。相反,香烟烟雾会刺激气道上皮中 COX-2 的表达。因此,有人假设吸烟者体内 PGE 水平升高会抑制 AERD 的发展,而戒烟可能会增加患 AERD 的易感性。
本研究旨在评估吸烟与 AERD 发病风险之间的关系。
比较了 114 例 AERD 患者的吸烟状况与两组对照人群,一组为经系统性阿司匹林激发试验诊断的阿司匹林耐受型哮喘患者(ATA-1,n=83),另一组为从大型数据集随机抽取的门诊患者(ATA-2,n=914),以及健康对照组(HC,n=2313)。
在哮喘发病年龄时,AERD 组的现吸烟率(9.7%)较低,但既往吸烟率(20.2%)较高,与 ATA-1 组(现吸烟率和既往吸烟率分别为 20.5%和 12.0%)、ATA-2 组(分别为 24.5%和 10.3%)和 HC 组(分别为 26.2%和 12.6%)相比。在校正混杂因素后,与 ATA-2 组相比(校正比值比[aOR]4.63,95%置信区间[CI]:2.16-9.93)和 HC 组(aOR 4.09,95% CI:2.07-8.05),AERD 与疾病发病前 1 至 4 年内戒烟呈正相关,这表明戒烟后可能会发生 AERD。
戒烟可能是 AERD 发病的危险因素。